Overview

Our Companies

Amenities

A Look Ahead

Overview

Finding flexible and affordable space can be an important step in the formation and growth of a successful company. Equally important is being located in an environment with a “critical mass” of entrepreneurs, innovators and sources of capital. Our world-class Port business incubator is one of only a handful of incubators in the region offering turnkey office and lab facilities, as well as access to shared lab equipment that is often too expensive for an early-stage company to purchase on its own. Beyond the physical infrastructure, the Port offers a strong connection to Greater Philadelphia’s innovation ecosystem and the ingredients startups need to grow and be successful. Residents can access Science Center networks and programs to capitalize and develop their businesses, while tapping into the rich pool of local talent to grow their workforce.

30+

incubator residents

250M+

in private capital raised by Port companies since 2012

$14M+

in government funding raised by Port residents since 2012

Our Companies

Home to a diverse group of early-stage companies in life sciences and emerging technologies, the Port business incubator at the Science Center in Philadelphia is often a startup’s first stop on its path to growth. Our residents are shaping the future of healthcare, energy, technology and beyond.

Developing a novel protein replacement strategy for treating mitochondrial diseases in patients. This technology will have broad application, should the company be successful in demonstrating activity in treating Friedreich’s Ataxia - a rare debilitating condition in which children and young adults progressively lose the ability to walk and speak as their hearts grow thick and weak before they eventually fail.

Solving a major process bottleneck in therapeutic protein production while significantly lowering the cost of goods for biotech and contract manufacturing companies. Our mission is to provide robust, flexible and cost-effective continuous manufacturing solutions to the biopharm industry using our proprietary CCTC technology platform.

Evogen
Developing a blood test for the rapid diagnosis of epilepsy. This blood test differentiates

epilepsy from other causes of seizures, sparing patients from unnecessary tests and inappropriate treatments.

Creates opportunities for low-income students by increasing their interest and exposure to Science, Technology, Engineering, and Mathematics (STEM) disciplines through inquiry- and project-based learning.

Kira Pharmaceutical

Lenima Field Diagnostic
Creating a point-of–care diagnostic test for infectious diseases in the gastrointestinal tract, blood stream, and respiratory tract. The test menu also includes novel cancer markers for screening high-risk individuals.

LignaMed
Developing a small molecule therapy to reduce side effects and increase effectiveness of radiation treatment for cancer. Synthesized from natural flaxseed, it has been shown to enhance chemotherapy and radiation treatment while protecting normal tissue from damage.

Oncoceutics
Developing a first-in-class small molecule cancer therapy. Targeting the most potent suppressor pathways in human cancer, its lead drug candidate, ONC201, is in clinical trials for multiple cancer indications.

Persistent Telecom Solutions
Developing and offering products and services for network service providers to manage network performance, service and reporting, and to predict faults and service level breaches.

Persona Partners
Helps companies develop brands that symbolize the values and ideals espoused by their target consumers. Driven by robust data analytics, the client brand comes to represent an identity that customers aspire to represent themselves.

RSC Worldwide
A subsidiary of the UK-based Royal Society of Chemistry, the company's main purpose is to help promote chemical science activities in North America.

SAB Technology
Generates protein particles that contain DNA to be delivered to cells with genetic defects, which could potentially correct the defects.

Telesis
Developing a small molecule therapy that inhibits the metabolic process in cancer cells to treat patients with solid tumors such as pancreatic cancer.

Vironika

A biotech startup whose primary mission is to discover and develop small molecule therapeutics to treat chronic viral infections and its associated diseases, including cancer and autoimmunity. Its secondary mission is to exploit viral latency to develop improved vectors for gene therapy and vaccine purposes.

Amenities

The Port is a turn-key facility catering to the flexible leasing needs of startup companies. Residents may select from a combination of fully furnished offices, cubicles, and wet and dry labs. Port staff leverages established networks to identify area resources that can help resident companies to grow and flourish.

All-inclusive with the Port’s easy-to-manage fee are:

Rent and utilities

Furniture and VOIP phone

24/7 access

On-site security

Internet connectivity and on-site IT support

Individual laboratory suites furnished with benches, casework, chemical hood, and built-in safety features such as safety shower and eye-wash station

3675 Market Street

A partnership to serve and strengthen entrepreneurship in Philadelphia.

Just as our resident companies experiment and innovate, the Science Center is innovating and iterating as well. Specifically, we’re taking our support for business incubation to the next level as we plan to move into our new building in 3675 Market Street in Summer 2018.

We’re partnering with globally recognized companies CIC and BioLabs to provide world-class office and lab facilities for startups at our new location in 3675 Market Street. This partnership will provide a significant boost for resident companies of the Science Center’s Port business incubator.

Companies will be able to take advantage of first-class lab and office facilities, premium shared equipment, a higher level of concierge services and access to CIC and BioLabs’ global networks – as well as access to the Science Center’s nationally recognized commercialization and accelerator programs that are focused on mentoring, funding, strategy development and resources to accelerate businesses. Together, we’re taking entrepreneurship and innovation to the next level. Join us.

The Port will remain open until the new building is complete, ensuring a seamless transition for resident companies. To learn more about CIC and BioLabs’ facilities in 3675 Market, click here.